Test Code | B0007 | |
Test Summary | This test detects alpha-galactosidase A activity. |
|
Turn-Around-Time (TAT)* | 3 days | |
Acceptable Sample Types | Dried Blood Spots Whole Blood (EDTA) |
|
Acceptable Billing Types |
Self (patient) Payment Institutional Billing
|
|
NY Approved | Yes | |
Self (patient) Price | $108.90 | |
Institutional Price | $108.90 | |
CPT Codes** | 83789 (x1) |
This test evaluates the activity of alpha-galactosidase A enzyme that has been associated with Fabry disease.
This test may be appropriate for individuals with a clinical suspicion of Fabry disease and/or individuals with a family history of Fabry disease.
Fabry disease is a lysosomal storage disorder with a wide spectrum of symptoms ranging from mild cases in females, to severe cases in classically affected hemizygous males. Symptoms may include abdominal and joint pain, vascular lesions and corneal abnormalities. Neurological symptoms include autonomic dysfunction and burning sensation or numbness in the extremities. Fabry disease affects an estimated 1 in 40,000 to 1 in 60,000 males. The prevalence is unknown in females.
Flow injection analysis tandem mass spectrometry (FIA/MS/MS)
Dried blood spot card
Follow kit instructions. Briefly, allow blood to saturate card until indicated areas are filled and blood has soaked through card. Air dry card at ambient temperature for at least 3 hours.
- NBS: Please contact PKIG to request the StepOne® kit.
- Gene Sequencing: Please contact PKIG to request the DBS collection kit.
- For pre-punched DBS: The required minimum 6 punches with 3.2 mm or 4 punches 4.75 mm.
EDTA (purple top)
Infants (< 2-years): 2 to 3 mL; Children (>2-years): 3 to 5 mL; Older children and adults: Minimum 5mL. The blood tube should be inverted several times immediately after blood collection to prevent coagulation.
Clotted or hemolyzed samples are not accepted.